Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Alzheimer's Disease

Free Subscription Articles published in BMJ Retrieve available abstracts of 28 articles: HTML format

Single Articles

July 2024
1. DYER O
   Scientist who worked on Cassava's Alzheimer drug simufilam charged with fraud.
   BMJ. 2024;386:q1568.
   PubMed    
   
   
   June 2024
2. DYER O
   Donanemab: FDA experts recommend approval of Alzheimer's drug.
   BMJ. 2024;385:q1327.
   PubMed    
   
   
   May 2024
3. NOLAN T
   A potential new treatment for Alzheimer's disease ... and other research.
   BMJ. 2024;385:q1125.
   PubMed    
   
   
   February 2024
4. IACOBUCCI G
   Sixty seconds on . . . Viagra and Alzheimer's disease.
   BMJ. 2024;384:q370.
   PubMed    
   
   
   
5. DYER O
   Aduhelm: Biogen abandons Alzheimer's drug after controversial approval left it unfunded by Medicare.
   BMJ. 2024;384:q281.
   PubMed    
   
   
   October 2023
6. DALY TP
   Informing consent to antibodies in Alzheimer's disease.
   BMJ. 2023;383:p2350.
   PubMed    
   
   
   August 2023
7. HOWARD R, Kales HC
   New treatments for Alzheimer's disease.
   BMJ. 2023;382:1852.
   PubMed    
   
   
   July 2023
8. IACOBUCCI G
   Donanemab leads to modest slowing of Alzheimer's progression, study finds.
   BMJ. 2023;382:p1659.
   PubMed    
   
   
   
9. MAHASE E
   Alzheimer's disease: Lecanemab gets full FDA approval and black box safety warning.
   BMJ. 2023;382:p1580.
   PubMed    
   
   
   June 2023
10. POURHADI N, Morch LS, Holm EA, Torp-Pedersen C, et al
    Menopausal hormone therapy and dementia: nationwide, nested case-control study.
    BMJ. 2023;381:e072770.
    PubMed     Abstract available
    
    
    March 2023
11. TANNE JH
    Lecanemab: US Veterans Health Administration will cover cost of new Alzheimer's drug.
    BMJ. 2023;380:p628.
    PubMed    
    
    
    January 2023
12. MAHASE E
    Alzheimer's disease: FDA approves lecanemab amid cost and safety concerns.
    BMJ. 2023;380:p73.
    PubMed    
    
    
    
13. TANNE JH
    Aduhelm: Approval of Alzheimer's drug was highly unorthodox, finds report.
    BMJ. 2023;380:p6.
    PubMed    
    
    
    December 2022
14. WALSH S, Merrick R, Richard E, Nurock S, et al
    Lecanemab for Alzheimer's disease.
    BMJ. 2022;379:o3010.
    PubMed    
    
    
    August 2022
15. DYER O
    Alzheimer's: Alleged image manipulation in seminal paper casts doubt on leading hypothesis of disease.
    BMJ. 2022;378:o2041.
    PubMed    
    
    
    April 2022
16. DHANA K, Franco OH, Ritz EM, Ford CN, et al
    Healthy lifestyle and life expectancy with and without Alzheimer's dementia: population based cohort study.
    BMJ. 2022;377:e068390.
    PubMed     Abstract available
    
    
    March 2022
17. DYER O
    Long delayed publication of data on Alzheimer's drug Aduhelm leaves questions unanswered.
    BMJ. 2022;376:o808.
    PubMed    
    
    
    January 2022
18. LYTHGOE MP, Jenei K, Prasad V
    Regulatory decisions diverge over aducanumab for Alzheimer's disease.
    BMJ. 2022;376:e069780.
    PubMed    
    
    
    December 2021
19. MAHASE E
    Aducanumab: European agency rejects Alzheimer's drug over efficacy and safety concerns.
    BMJ. 2021;375:n3127.
    PubMed    
    
    
    November 2021
20. HAMILTON F, West C
    Predatory marriage: Doctors can help to spot and prevent this exploitation.
    BMJ. 2021;375:n2906.
    PubMed    
    
    
    September 2021
21. VINOGRADOVA Y, Dening T, Hippisley-Cox J, Taylor L, et al
    Use of menopausal hormone therapy and risk of dementia: nested case-control studies using QResearch and CPRD databases.
    BMJ. 2021;374:n2182.
    PubMed     Abstract available
    
    
    August 2021
22. ILIFFE S, Manthorpe J
    Aducanumab, amyloid, and culture wars.
    BMJ. 2021;374:n2038.
    PubMed    
    
    
    July 2021
23. DYER O
    FDA calls for investigation into industry influence during Alzheimer's drug approval.
    BMJ. 2021;374:n1778.
    PubMed    
    
    
    
24. WALSH S, Merrick R, Milne R, Brayne C, et al
    Aducanumab for Alzheimer's disease?
    BMJ. 2021;374:n1682.
    PubMed    
    
    
    June 2021
25. MAHASE E
    Three FDA advisory panel members resign over approval of Alzheimer's drug.
    BMJ. 2021;373:n1503.
    PubMed    
    
    
    
26. MAHASE E
    FDA approves controversial Alzheimer's drug despite uncertainty over effectiveness.
    BMJ. 2021;373:n1462.
    PubMed    
    
    
    February 2021
27. ACKLEY SF, Zimmerman SC, Brenowitz WD, Tchetgen Tchetgen EJ, et al
    Effect of reductions in amyloid levels on cognitive change in randomized trials: instrumental variable meta-analysis.
    BMJ. 2021;372:n156.
    PubMed     Abstract available
    
    
    October 2020
28. SHI J, Sabbagh MN, Vellas B
    Alzheimer's disease beyond amyloid: strategies for future therapeutic interventions.
    BMJ. 2020;371:m3684.
    PubMed    
    
    

Thank you for your interest in scientific medicine.

AMEDEO Alzheimer's Disease is free of charge.